VIRIDIAN THERAPEUTICS INC

Viridian insiders buy 32,341 shares post FDA approval for its TED therapy—signaling confidence, lock‑up stability, and a bullish outlook for the company’s orphan drug pipeline.

Fairmount’s $17.00 buy of 1.18 M Viridian shares signals institutional confidence that the $342 M capital raise will fuel safe, efficacious Phase 3 trials for the company’s promising TED therapy, VT‑101, and help secure a breakthrough‑therapy design…